ImmunityBio Inc. Common Stock vs Kenvue Inc. Common Stock — how do they compare? ImmunityBio Inc. Common Stock trades at $10.57 (market cap $10.51B), while Kenvue Inc. Common Stock trades at $17.68 (market cap $34.06B). The key difference: Kenvue Inc. Common Stock is far larger — about 3.2× ImmunityBio Inc. Common Stock's market cap, and Kenvue Inc. Common Stock pays a 4.74% dividend while ImmunityBio Inc. Common Stock pays none. Which is the better fit depends on your goals.
| IBRX | KVUE | |
|---|---|---|
Market Cap | $10.51B | $34.06B |
Volume | 10,445,785 | 23,267,228 |
Sector | Health | Consumer Staples |
52-Week High | $11.55 | $19.83 |
52-Week Low | $1.98 | $14.11 |
Typical Hold Time | 1 Days | — |
Enterprise Value | $10.97B | $41.56B |
Dividend Yield | — | 4.74% |
Trailing returns across standard periods
Latest headlines on both assets
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →Kenvue is a consumer health company that markets personal care, self-care, and skin health products. Its brands include Tylenol, Listerine, Neutrogena, Johnson’s, BAND-AID Brand, Aveeno, and Zyrtec.
Read more on KVUE →